DK1921077T3 - Middel til behandling og/eller forebyggelse af søvnforstyrrelse - Google Patents

Middel til behandling og/eller forebyggelse af søvnforstyrrelse Download PDF

Info

Publication number
DK1921077T3
DK1921077T3 DK06782197.5T DK06782197T DK1921077T3 DK 1921077 T3 DK1921077 T3 DK 1921077T3 DK 06782197 T DK06782197 T DK 06782197T DK 1921077 T3 DK1921077 T3 DK 1921077T3
Authority
DK
Denmark
Prior art keywords
compound
nmr
ppm
furyl
thiazol
Prior art date
Application number
DK06782197.5T
Other languages
English (en)
Inventor
Noriaki Uesaka
Shunji Ichikawa
Takao Nakajima
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Application granted granted Critical
Publication of DK1921077T3 publication Critical patent/DK1921077T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (16)

1. Thiazolderivat gengivet ved en hvilken som helst af følgende formler (1), (5), (7), (8), (11), (78), (95), (99), (114), (136), (142), (157), (336), (360), (361), (365), (367), (373), (376), (407), (409), (416), (420), (463) og (508):
eller et farmaceutisk acceptabelt salt deraf, til anvendelse i behandling og/eller forebyggelse af hypersomni og/eller en søvnforstyrrelse forbundet med søvnighed i dagtimerne.
2. Thiazolderivat eller farmaceutisk acceptabelt salt deraf til anvendelse i behandling og/eller forebyggelse af hypersomni og/eller en søvnforstyrrelse forbundet med søvnighed i dagtimerne ifølge krav 1, hvor thiazolderivatet er som gengivet ved en hvilken som helst af de følgende formler (78), (95), (99), (114), (136), (142), (157), (336), (360), (361), (365), (367), (373), (376), (407), (409), (416), (420), (463), og (508).
3. Thiazolderivat eller farmaceutisk acceptabelt salt deraf til anvendelse i behandling og/eller forebyggelse af hypersomni og/eller en søvnforstyrrelse forbundet med søvnighed i dagtimerne ifølge krav 1, hvor thiazolderivatet er som gengivet ved en hvilken som helst af de følgende formler (95), (99), (114), (136), (142), og (157).
4. Thiazolderivat eller farmaceutisk acceptabelt salt deraf til anvendelse i behandling og/eller forebyggelse af hypersomni og/eller en søvnforstyrrelse forbundet med søvnighed i dagtimerne ifølge krav 1, hvor thiazolderivatet er som gengivet ved en hvilken som helst af de følgende formler (360), (361), (365), (367), (373), (376), (407), (409), (416), (420), og (463).
5. Thiazolderivat eller farmaceutisk acceptabelt salt deraf til anvendelse i behandling og/eller forebyggelse af hypersomni og/eller en søvnforstyrrelse forbundet med søvnighed i dagtimerne ifølge krav 1, hvor thiazolderivatet er som gengivet ved følgende formel (136).
6. Thiazolderivat eller farmaceutisk acceptabelt salt deraf til anvendelse i behandling og/eller forebyggelse af hypersomni og/eller en søvnforstyrrelse forbundet med søvnighed i dagtimerne ifølge krav 1, hvor thiazolderivatet er som gengivet ved følgende formel (409).
7. Thiazolderivat eller farmaceutisk acceptabelt salt deraf til anvendelse i behandling og/eller forebyggelse af hypersomni og/eller en søvnforstyrrelse forbundet med søvnighed i dagtimerne ifølge krav 1, hvor thiazolderivatet er som gengivet ved følgende formel (463).
8. Thiazolderivat eller farmaceutisk acceptabelt salt deraf til anvendelse i behandling og/eller forebyggelse af hypersomni og/eller en søvnforstyrrelse forbundet med søvnighed i dagtimerne ifølge et hvilket som helst af kravene 1 til 7, hvor hypersomnien og/eller søvnforstyrrelsen forbundet med søvnighed i dagtimerne er hypersomni.
9. Thiazolderivat eller farmaceutisk acceptabelt salt deraf til anvendelse i behandling og/eller forebyggelse af hypersomni og/eller en søvnforstyrrelse forbundet med søvnighed i dagtimerne ifølge et hvilket som helst af kravene 1 til 7, hvor hypersomnien og/eller søvnforstyrrelsen forbundet med søvnighed i dagtimerne er narkolepsi, tilbagevendende hypersomni (periodisk hypersomni), idiopatisk hypersomni eller posttraumatisk hypersomni.
10. Thiazolderivat eller farmaceutisk acceptabelt salt deraf til anvendelse i behandling og/eller forebyggelse af hypersomni og/eller en søvnforstyrrelse forbundet med søvnighed i dagtimerne ifølge et hvilket som helst af kravene 1 til 7, hvor hypersomnien og/eller søvnforstyrrelsen forbundet med søvnighed i dagtimerne er døgnrytme-søvnforstyrrelse.
11. Thiazolderivat eller farmaceutisk acceptabelt salt deraf til anvendelse i behandling og/eller forebyggelse af hypersomni og/eller en søvnforstyrrelse forbundet med søvnighed i dagtimerne ifølge et hvilket som helst af kravene 1 til 7, hvor behandlingen og/eller forebyggelsen af hypersomni og/eller en søvnforstyrrelse forbundet med søvnighed i dagtimerne forbedrer søvnighedstilstanden i dagtimerne.
12. Anvendelse af thiazolderivatet gengivet ved en hvilken som helst af følgende formler (1), (5), (7), (8), (11), (78), (95), (99), (114), (136), (142), (157), (336), (360), (361), (365), (367), (373), (376), (407), (409), (416), (420), (463) og (508):
eller et farmaceutisk acceptabelt salt deraf til fremstilling af et terapeutisk eller og/eller forebyggende middel mod hypersomni og/eller en søvnforstyrrelse forbundet med søvnighed i dagtimerne.
13. Anvendelse ifølge krav 12, hvor hypersomnien og/eller søvnforstyrrelsen forbundet med søvnighed i dagtimerne er hypersomni.
14. Anvendelse ifølge krav 12, hvor hypersomnien og/eller søvnforstyrrelsen forbundet med søvnighed i dagtimerne er narkolepsi, tilbagevendende hypersomni (periodisk hypersomni), idiopatisk hypersomni eller posttraumatisk hypersomni.
15. Anvendelse ifølge krav 12, hvor hypersomnien og/eller søvnforstyrrelsen forbundet med søvnighed i dagtimerne er forbundet med døgnrytme-søvnforstyrrelse.
16. Anvendelse ifølge krav 12, hvor det terapeutiske og/eller forebyggende middel mod hypersomni og/eller en søvnforstyrrelse forbundet med søvnighed i dagtimerne er til forbedring af søvnighedstilstanden i dagtimerne.
DK06782197.5T 2005-08-02 2006-08-02 Middel til behandling og/eller forebyggelse af søvnforstyrrelse DK1921077T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005223547 2005-08-02
PCT/JP2006/315328 WO2007015528A1 (ja) 2005-08-02 2006-08-02 睡眠障害の治療および／または予防剤

Publications (1)

Publication Number Publication Date
DK1921077T3 true DK1921077T3 (da) 2017-10-23

Family

ID=37708808

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06782197.5T DK1921077T3 (da) 2005-08-02 2006-08-02 Middel til behandling og/eller forebyggelse af søvnforstyrrelse

Country Status (14)

Country Link
US (1) US7928098B2 (da)
EP (1) EP1921077B1 (da)
JP (1) JP5121453B2 (da)
CA (1) CA2617817C (da)
CY (1) CY1119488T1 (da)
DK (1) DK1921077T3 (da)
ES (1) ES2643340T3 (da)
HU (1) HUE034666T2 (da)
LT (1) LT1921077T (da)
PL (1) PL1921077T3 (da)
PT (1) PT1921077T (da)
SI (1) SI1921077T1 (da)
TW (1) TWI457125B (da)
WO (1) WO2007015528A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0418082B8 (pt) * 2003-12-26 2021-05-25 Kyowa Hakko Kirin Co Ltd derivados de tiazol úteis como antagonistas de receptor de adenosina a2a
AU2005287729A1 (en) 2004-09-22 2006-03-30 H. Lundbeck A/S 2-acylaminothiazole derivatives
US7674912B2 (en) 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
AU2007288245A1 (en) 2006-08-24 2008-02-28 Novartis Ag 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyrazol-3-yl) -thiazole derivatives as well as related compounds as stearoyl-CoA desaturase (SCD) inhibitors for the treatment of metabolic, cardiovascular and other disorders
JP5351025B2 (ja) 2006-09-22 2013-11-27 ノバルティス アーゲー ヘテロ環式有機化合物
MX2009006728A (es) 2006-12-20 2009-09-09 Novartis Ag Heterociclos de 5 miembros 2-sustituidos como inhibidores de scd.
AU2009274876C1 (en) 2008-07-23 2016-08-18 Kyowa Kirin Co., Ltd. Therapeutic agent for migraine
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA110097C2 (uk) 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
UA113383C2 (xx) 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
AU2011293201B2 (en) * 2010-08-27 2015-11-05 Calcimedica Inc. Compounds that modulate intracellular calcium
UY34832A (es) 2012-05-31 2013-12-31 Phenex Pharmaceuticals Ag TIAZOLES SUSTITUIDOS POR CARBOXAMIDA O SULFONAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUÉRFANO RORy (lambda)
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
HRP20210484T1 (hr) * 2014-12-04 2021-06-25 Procomcure Biotech Gmbh Antimikrobna sredstva koja se temelje na imidazolu
US10314820B2 (en) * 2014-12-04 2019-06-11 Procomcure Biotech Gmbh Imidazole-based heterocyclic compounds
JOP20200093A1 (ar) 2015-01-09 2017-06-16 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول
US20180243298A1 (en) * 2015-04-02 2018-08-30 Abbvie Inc. Trpv3 modulators
EP3280414B1 (en) * 2016-04-15 2023-08-23 Oxford University Innovation Limited Adenosine receptor modulators for the treatment of circadian rhythm disorders
CN109293652B (zh) * 2017-07-24 2021-10-22 四川科伦博泰生物医药股份有限公司 一种取代的噻唑衍生物及其用途
WO2023111996A1 (en) 2021-12-17 2023-06-22 Reglagene Holding, Inc. Compositions and methods of making and using small molecules in the treatment of cancer
KR20250176573A (ko) * 2023-02-28 2025-12-19 레글라진, 아이엔씨. 건강 상태의 치료를 위한 소분자 제조 및 사용을 위한 조성물 및 방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2677356B1 (fr) 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
ATE257703T1 (de) * 1997-10-27 2004-01-15 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
WO1999064418A1 (en) 1998-06-05 1999-12-16 Novartis Ag Aryl pyridinyl thiazoles
IL146105A (en) * 1999-04-23 2005-09-25 Tadeda Pharmaceutical Company 5-pyridyl-1, 3-azole compounds, process for producing the same and use therefor
JP3333774B2 (ja) 1999-04-23 2002-10-15 武田薬品工業株式会社 ５−ピリジル−１，３−アゾール化合物、その製造法及び用途
JP2002302488A (ja) * 2000-03-30 2002-10-18 Takeda Chem Ind Ltd 置換１，３−チアゾール化合物、その製造法および用途
EP1268474A2 (en) * 2000-03-30 2003-01-02 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
US6643966B2 (en) * 2001-03-05 2003-11-11 Anthony J. Schmitt Banner sign display stand
JPWO2002079204A1 (ja) * 2001-03-28 2004-07-22 協和醗酵工業株式会社 ８−チアゾリル［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
TWI330183B (da) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
EP1441732A2 (en) 2001-11-08 2004-08-04 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivative and pharmaceutical use thereof
GB0130705D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Chemical compounds
TW200524887A (en) * 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
BRPI0418082B8 (pt) * 2003-12-26 2021-05-25 Kyowa Hakko Kirin Co Ltd derivados de tiazol úteis como antagonistas de receptor de adenosina a2a
AU2005287729A1 (en) 2004-09-22 2006-03-30 H. Lundbeck A/S 2-acylaminothiazole derivatives
US20100280023A1 (en) 2005-06-23 2010-11-04 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives

Also Published As

Publication number Publication date
JPWO2007015528A1 (ja) 2009-02-19
WO2007015528A1 (ja) 2007-02-08
HUE034666T2 (hu) 2018-02-28
ES2643340T3 (es) 2017-11-22
JP5121453B2 (ja) 2013-01-16
CA2617817C (en) 2014-05-27
PL1921077T3 (pl) 2018-01-31
EP1921077B1 (en) 2017-07-26
CA2617817A1 (en) 2007-02-08
CY1119488T1 (el) 2018-03-07
US20100152162A1 (en) 2010-06-17
EP1921077A4 (en) 2009-01-28
TWI457125B (zh) 2014-10-21
US7928098B2 (en) 2011-04-19
SI1921077T1 (sl) 2017-11-30
EP1921077A1 (en) 2008-05-14
TW200740434A (en) 2007-11-01
PT1921077T (pt) 2017-10-26
LT1921077T (lt) 2017-09-25

Similar Documents

Publication Publication Date Title
DK1921077T3 (da) Middel til behandling og/eller forebyggelse af søvnforstyrrelse
AU2004309279B2 (en) Thiazole derivative
CN101472902A (zh) 新哌嗪化合物及其作为hcv聚合酶抑制剂的用途
WO2019043407A1 (en) DERIVATIVES OF 2-AZABICYCLO [3.1.1] HEPTANE AND 2-AZABICYCLO [3.2.1] OCTANE SUBSTITUTED AS OREXIN RECEPTOR ANTAGONISTS
EP1894930A1 (en) Thiazole derivative
EP3472149A1 (en) Heterocyclic prolinamide derivatives
MXPA06007357A (en) Thiazole derivative
HK1224660B (en) Thiazole derivatives
HK1224660A1 (en) Thiazole derivatives
HK1091837B (en) Thiazole derivative